Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

@article{Keymeulen2009FouryearMO,
  title={Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass},
  author={Bart Keymeulen and Markus Walter and Chantal Mathieu and Leonard Kaufman and Frans K. Gorus and Robert Hilbrands and Evy Vandemeulebroucke and Ursule Van de Velde and Laurent Crenier and Christophe E. De Block and Sophie Candon and Herman Waldmann and Anette-G. Ziegler and Lucienne Chatenoud and Daniel G. Pipeleers},
  journal={Diabetologia},
  year={2009},
  volume={53},
  pages={614-623}
}
The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. Eighty patients, aged 12–39 years, were recruited for a phase 2 multicentre trial and randomised to placebo (n = 40) or ChAglyCD3 (n = 40) treatment by a third party member; participants and care-givers were blinded. The change in insulin dose (U kg−1 day−1) over 48 months was chosen as primary endpoint and compared in 31 placebo- and 33… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 116 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

A single course of anti - CD 3 monoclonal antibody hOKT 3 gamma 1 ( Ala - Ala ) results in improvement in C - peptide responses and clinical parameters for at least 2 years after onset of type 1

  • KC Herold, SE Gitelman, U Masharani
  • DIABETES
  • 2005

Similar Papers

Loading similar papers…